In conclusion, we identify a transcriptional regulatory mechanism for KEAP1 and G6PD and provide a strong rationale for therapies that include Nrf2i or G6PDi combined with BRD4 inhibitors for SCLC patients in the clinic. The gene discussed is KEAP1; the disease is small cell lung carcinoma.